A new treatment to stop cancer growth and spread
An engineered prodrug for inhibition of cancer growth and metastasis
This study is testing a new treatment for patients with advanced cancers like ovarian, lung, and colon cancer, using a special drug that targets cancer cells directly to help improve how well the treatment works and increase the chances of lasting recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11047171 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for metastatic and recurrent solid tumors, such as ovarian, lung, and colon cancers. It aims to create an engineered prodrug that utilizes anthrax toxin proteins to selectively target and deliver potent cytotoxins to cancer cells. By exploiting specific enzymes found on the surface of malignant tumors, this approach seeks to overcome the challenges posed by chemotherapy resistance and improve long-term remission rates. Patients may benefit from a more effective therapeutic strategy tailored to the unique biology of their tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic or recurrent solid tumors, particularly those with ovarian, lung, or colon cancers.
Not a fit: Patients with early-stage cancers or those not diagnosed with solid tumors may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with advanced cancers that are currently difficult to manage.
How similar studies have performed: While this approach is innovative, similar strategies targeting tumor-specific mechanisms have shown promise in other research, indicating potential for success.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Antalis, Toni M — University of Maryland Baltimore
- Study coordinator: Antalis, Toni M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.